香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十二次會議決議公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 4 月 29 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 2、《关于召开公司 2024 年年度股东大会 ...

Financial Performance - The company achieved operating revenue of RMB 70.763 billion in Q1 2025, representing a year-on-year growth of 0.87%[10] - The net profit attributable to shareholders was RMB 1.333 billion, a decrease of 13.56% year-on-year, with the industrial segment contributing RMB 532 million and the commercial segment contributing RMB 834 million[10] - Total operating revenue for the reporting period was approximately 70.76 billion RMB, an increase of 0.87% compared to the previous year[20] - Net profit attributable to shareholders decreased by 13.56% to approximately 1.33 billion RMB[20] - Net profit for Q1 2025 was ¥1.64 billion, a decrease of 12.06% from ¥1.87 billion in Q1 2024[36] - Earnings per share for Q1 2025 were ¥0.36, down from ¥0.42 in Q1 2024[38] Research and Development - Research and development expenses amounted to RMB 612 million, with R&D costs at RMB 497 million remaining stable year-on-year[11] - Multiple innovative drug research pipelines are progressing, including I001 for hypertension, which has submitted supplementary materials for review[12] - The company has established several key laboratories and centers to enhance its R&D capabilities in the biopharmaceutical industry[13] - The company is actively collaborating with academic institutions to advance research in traditional Chinese medicine and improve product quality[17] - The company reported a decrease in R&D expenses to ¥497 million in Q1 2025 from ¥501 million in Q1 2024[35] - Research and development expenses for Q1 2025 were 101,363,079.95, down from 123,475,536.87 in Q1 2024, indicating an 18% reduction[50] Product Development and Approvals - The company received production approvals for two products and submitted eight additional products for production during the reporting period[13] - A total of 77 products (106 specifications) have passed quality and efficacy consistency evaluations as of the end of the reporting period[13] - The company is implementing a strategy to ensure the quality of medicinal materials through a comprehensive national resource network and standardized management models[15] Business Segments Performance - Innovative business segments, including import agency and innovative drug services, have shown good growth during the reporting period[16] - The company's total import agency business achieved sales revenue of 8.6 billion RMB, a year-on-year increase of 9.0%[18] - The innovative drug full life cycle service generated sales revenue of 12.5 billion RMB, with a year-on-year growth of 23.2%[18] - The CSO business saw a revenue increase of 9.89% year-on-year[18] - The medical device health business reported sales revenue of 10.9 billion RMB, reflecting a year-on-year growth of 6.9%[18] Cash Flow and Liquidity - The net cash flow from operating activities improved by 59.73%, reaching approximately -2.20 billion RMB[20] - In Q1 2025, the cash inflow from operating activities was CNY 72.34 billion, an increase of 3.9% from CNY 67.81 billion in Q1 2024[40] - The net cash flow from operating activities was -CNY 2.20 billion, an improvement from -CNY 5.47 billion in the same period last year[41] - Cash inflow from investment activities totaled CNY 16.46 billion, up from CNY 10.53 billion in Q1 2024, marking a 56% increase[41] - Cash inflow from financing activities reached CNY 23.25 billion, compared to CNY 21.52 billion in Q1 2024, reflecting an 8% increase[42] - The company experienced a net decrease in cash and cash equivalents of approximately ¥1.63 billion in Q1 2025, compared to a decrease of approximately ¥1.08 billion in Q1 2024[54] Assets and Liabilities - Total assets at the end of the reporting period were approximately 225.87 billion RMB, a 2.11% increase from the previous year[20] - Total liabilities increased to CNY 130,813,134,867.82 from CNY 126,038,386,279.10, marking an increase of approximately 3.1%[31] - Short-term borrowings rose significantly to CNY 42,909,928,847.57 from CNY 38,064,098,967.71, reflecting an increase of about 12.4%[31] - Total liabilities as of March 31, 2025, amounted to ¥140.57 billion, an increase from ¥137.47 billion as of December 31, 2024[32] - Total non-current liabilities were ¥9.76 billion as of March 31, 2025, down from ¥11.43 billion as of December 31, 2024[32] Shareholder Information - The total number of shares outstanding as of March 31, 2025, is 3,708,361,809, with A-shares accounting for 2,789,289,105 and H-shares for 919,072,704[28] - The number of ordinary shareholders reached 80,068, with A-share holders accounting for 78,411 and H-share holders for 1,657[28] - Shareholders' equity attributable to the parent company increased to ¥73.01 billion as of March 31, 2025, from ¥71.68 billion as of December 31, 2024[32] Future Outlook - The company is set to implement new accounting standards starting in 2025, which may impact future financial reporting[54]

Financial Performance - The company achieved operating revenue of RMB 70.76 billion, a year-on-year increase of 0.87%[7] - Net profit attributable to shareholders decreased by 13.56% to RMB 1.33 billion, while the net profit excluding non-recurring gains and losses was RMB 1.26 billion, down 8.10%[19] - The innovative drug business achieved sales revenue of RMB 12.5 billion, marking a year-on-year growth of 23.2%[16] - The medical device health business reported sales revenue of RMB 10.9 billion, an increase of 6.9%[18] - Total revenue for Q1 2025 reached CNY 70.76 billion, a slight increase of 0.87% compared to CNY 70.15 billion in Q1 2024[31] - The company reported a net profit of CNY 1.09 billion for Q1 2025, compared to CNY 0.26 billion in Q1 2024, indicating a significant increase[31] - Net profit attributable to shareholders for Q1 2025 was approximately ¥1.33 billion, down 13.5% from ¥1.54 billion in Q1 2024[32] - Total comprehensive income for Q1 2025 was approximately ¥1.64 billion, a decrease of 12.3% compared to ¥1.87 billion in Q1 2024[33] Research and Development - Research and development expenses amounted to RMB 6.12 billion, with R&D costs at RMB 4.97 billion, remaining stable year-on-year[7] - The company is advancing multiple innovative drug research pipelines and has established several key laboratories to enhance its R&D capabilities[9] - Research and development expenses for Q1 2025 were CNY 101.36 million, down from CNY 123.48 million in Q1 2024, showing a decrease of about 18%[43] Assets and Liabilities - Total assets reached RMB 225.87 billion, up 2.11% from the end of the previous year[19] - Total assets as of March 31, 2025, amounted to CNY 225.87 billion, up from CNY 221.21 billion at the end of 2024[29] - Total liabilities increased to CNY 140.57 billion, compared to CNY 137.47 billion at the end of 2024[29] - The company's total equity decreased to CNY 40.39 billion as of March 31, 2025, from CNY 40.45 billion as of December 31, 2024, a decline of approximately 0.15%[41] Cash Flow - The net cash flow from operating activities increased by 59.73%, driven by a rise in received payments[21] - Cash flow from operating activities for Q1 2025 showed a net outflow of approximately ¥2.20 billion, an improvement from a net outflow of ¥5.47 billion in Q1 2024[37] - Cash inflow from investment activities in Q1 2025 was approximately ¥16.46 billion, significantly higher than ¥10.53 billion in Q1 2024[37] - Cash flow from financing activities for Q1 2025 was approximately ¥3.86 billion, an increase from ¥3.25 billion in Q1 2024[38] - The company's cash and cash equivalents at the end of Q1 2025 totaled approximately ¥32.57 billion, up from ¥27.13 billion at the end of Q1 2024[38] Shareholder Information - The company has 80,068 total common shareholders at the end of the reporting period[23] - HKSCC NOMINEES LIMITED holds 918,228,849 shares, representing 24.7% of total shares[23] - The top ten shareholders collectively hold significant stakes, with the largest being HKSCC NOMINEES LIMITED and Shanghai Pharmaceutical Group[23] - The total number of shares outstanding is 3,708,361,809, with 2,789,289,105 A-shares and 919,072,704 H-shares[24] Other Financial Metrics - The weighted average return on net assets decreased by 0.39 percentage points to 1.84%[19] - The company's long-term borrowings due within one year increased by 163.19% during the reporting period[21] - The asset disposal income decreased by 100.82%, indicating a reduction in gains from the disposal of fixed and intangible assets[21] - The company reported a net loss from non-current asset disposal of 455,500.64, reflecting challenges in asset management[20] - The financial expenses for Q1 2025 were CNY 52.24 million, down from CNY 59.98 million in Q1 2024, representing a decrease of about 12.9%[43] - The investment income for Q1 2025 was CNY 95.97 million, an increase from CNY 72.12 million in Q1 2024, reflecting a growth of approximately 33.1%[43]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代碼: 02607) 於2025年4月25日，本次收購已完成交割，交割後上海和黃各股東持股情況的詳情載列如下。 上海和黃由本公司直接及間接持有60%股權，成為本公司的非全資附屬公司，且其財務業績 合併計入本集團綜合財務報表內。 | 序號 | 股東名稱 | 認繳出資額 | 實繳出資額 | 持股比例 | | --- | --- | --- | --- | --- | | | | (人民幣/萬元) | (人民幣/萬元) | (%) | | 1. | 和黃投資 | 1,145 | 1,145 | 5.0000% | | 2. | 上藥藥材 | 11,450 | 11,450 | 50.0000% | | 3. | 本公司 | 2,290 | 2, ...

上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） | 關於本報告 | 001 | | --- | --- | | 董事長致辭 | 003 | | 走進上海醫藥 | 005 | | 年度專題： | 013 | 科技引領醫療創新 攜手共繪健康藍圖 | 可持續發展治理體系 | 021 | | --- | --- | | 可持續發展治理模型 | 023 | | 利益相關方識別與溝通 | 026 | | 雙重重要性分析 | 027 | | 響應聯合國可持續發展目標（SDGs） | 029 | | 守正篤行， 同德共鑄發展根基 | 031 | | 黨建引領發展 | 033 | | --- | --- | | 穩健公司治理 | 034 | | 堅持合規運營 | 039 | | 深化數字化運營 | 049 | | 向新而行， | 051 | | --- | --- | | 同力共築健康中國 | | | 創新驅動發展 | 053 | | 提升健康可及 | 057 | | 卓越品質保障 | 064 ...

Financial Performance - Shanghai Pharmaceuticals Group reported a revenue increase of 12% year-on-year for the fiscal year 2024, reaching RMB 50 billion[3]. - The company achieved a net profit of RMB 5 billion, representing a growth of 15% compared to the previous year[3]. - Revenue for 2023 reached RMB 260.30 billion, an increase of 12.2% compared to 2022[17]. - Pre-tax profit for 2023 was RMB 7.05 billion, a decrease of 20% from 2022[17]. - The company achieved a net profit of RMB 5.17 billion for 2023, down 26.2% from the previous year[17]. - In 2024, the company achieved operating revenue of RMB 275.25 billion, a year-on-year increase of 5.75%[25]. - The net profit attributable to shareholders reached RMB 4.55 billion, up 20.82% year-on-year[26]. - The pharmaceutical industrial segment reported sales revenue of RMB 23.73 billion, a decline of 9.62% year-on-year, while the pharmaceutical commercial segment saw sales revenue of RMB 251.52 billion, an increase of 7.47%[25]. - The company reported a net operating cash flow of RMB 5.83 billion, an increase of 11.39% year-on-year, indicating high-quality development[28]. - The company's operating revenue for the reporting period reached ¥275.25 billion, an increase of 5.75% compared to ¥260.30 billion in the same period last year[55]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[3]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[7]. - The company has completed its first-year sales targets in Thailand and initiated operations in the Philippines and the UAE, marking significant international expansion[43]. - The company aims to leverage Hong Kong as a strategic hub to promote traditional Chinese medicine globally, aligning with national development strategies[43]. - The company is exploring opportunities in international markets to diversify its revenue streams and reduce dependency on domestic sales[198]. Research and Development - Shanghai Pharmaceuticals is investing RMB 1 billion in new product development, focusing on innovative drug formulations[3]. - The company plans to enhance its innovative drug pipeline, with one new drug approved for market and several others advancing in clinical stages[21]. - Research and development investment totaled RMB 2.82 billion, with R&D expenses of RMB 2.39 billion, reflecting an 8.64% year-on-year growth[27]. - The company has established partnerships with top universities to promote innovation in drug development[20]. - The company aims to enhance existing products and potential products through marketing reforms, technology upgrades, and supply chain optimization[33]. - The company is focusing on both new product launches and existing product approvals to drive growth[71]. - The company is committed to continuous innovation and development in its pharmaceutical offerings[71]. Digital Transformation and Technology - Shanghai Pharmaceuticals aims to enhance its digital health services, with a projected investment of RMB 500 million over the next two years[3]. - The digital transformation initiatives have led to the recognition of the company’s smart factory as a national excellence-level facility[21]. - The company is leveraging digital technologies to improve customer engagement and streamline operations[200]. - A new marketing strategy has been implemented, focusing on digital channels, which is expected to increase customer engagement by 30%[8]. Sustainability and Corporate Responsibility - The company is committed to sustainability initiatives, with plans to reduce carbon emissions by 20% by 2025[3]. - The company’s environmental policies and performance are detailed in its 2024 Corporate Social Responsibility Report[158]. - The company disclosed its charitable contributions in the 2024 Sustainable Development Report and ESG Report[97]. Human Resources and Management - The company employed a total of 49,402 staff, with 19,370 in sales and 15,152 in production roles[170]. - The company has a total of 180 employees with doctoral degrees and 2,336 with master's degrees[170]. - The company has implemented a comprehensive training program for new employees, achieving full coverage with over 2,700 participants in 2024[175]. - The company has established a differentiated compensation system for various roles, including management, marketing, R&D, and production personnel, to align with performance and market conditions[171]. Financial Guidance and Future Outlook - The company has set a performance guidance of 10-15% revenue growth for the next fiscal year[3]. - The company provided guidance for the next quarter, expecting revenue to be between $1.3 billion and $1.4 billion, indicating a growth rate of 10% to 15%[3]. - Future outlook includes a commitment to research and development of new drugs and technologies to meet evolving healthcare needs[200]. - Overall, the management remains optimistic about achieving long-term growth targets despite market challenges[199].

海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於鹽酸纈更昔洛韋片獲得美國 FDA 批准文號的公告》、 《上海醫藥集團股份有限公司關於召開 2025 年第一季度業績說明會的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 中國上海，2025 年 4 月 23 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司 ） （股份代碼：02607） 關連交易 擬參與設立生物醫藥併購基金 最新進展 茲提述上海醫藥集團股份有限公司（「本公司」）日期為2025年1月28日的公告（「該公 告」），內容有關，本公司擬參與設立生物醫藥併購基金。除另有界定外，本公告所 用詞彙與該公告所界定者具有相同涵義。 訂立合夥協議及完成工商設立手續 董事會欣然宣佈，於2025年3月26日，本公司與國投先導（作為有限合夥人）、東富龍 （作為有限合夥人）、君實生物（作為有限合夥人）、鎂信健康（作為有限合夥人）、 浦東引領區基金（作為有限合夥人）、張江科技（作為有限合夥人）、興嘉二期（作 為有限合夥人）、馬陸發展（作為有限合夥人）、新華保險（作為有限合夥人）、中 贏創新（作為有限合夥人）、上實資本 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 董事會會議通告 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年四月十四日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先 生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、 王忠先生及萬鈞女士。 * 僅供識別 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈， 董事會會議將於二零二五年四月二十八日（星期一）舉行，藉以（其中包括） 批准本公司及其附屬公司截至二零二五年三月三十一日止三個月之第一季度業 績及其發佈。 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十一次會議決議公告》、《上海醫藥集 團股份有限公司關於高級管理人員變動的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 4 月 9 日 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 1、《关于聘任公司高级管理人员的议案》 同意聘任周亚栋女士担任公司副总裁兼财务总监，任期至第八届董事会届满 时止。同时沈波先生不再担任公司财务总监职务。 证券代码：6016 ...